Beyond Genomics of Waltham Mass., has appointed members to its newly formed research and development advisory board: Arnold Levine, a professor at the Cancer Institute of New Jersey and the former president of Rockefeller University, and Jeffrey Friedman, a professor at Rockefeller University, will be co-chairs of the board. The other members are
David Jackson, Jan van der Greef, Victor Dzau, Marc Kirschner, Douglas Lauffenburger,
and Christopher Sander.
Richard Dondero has become vice president for research and development at New Brunswick, NJ-based Senesco Technologies. Most recently, he was a group leader in the proteomics reagent manufacturing arm of Molecular Staging. Dondero holds an MS in biology from Seton Hall University in South Orange, NJ, and a BA in biology/chemistry from New Jersey City University.
Laura Francis will leave her post as chief financial officer and treasurer of Bruker BioSciences for personal reasons and “to pursue other interests,” Bruker said on Thursday. She will retain her current position until Sept. 1 to help ensure a smooth transition. Bruker said it will start searching for a new CFO, to be based at its Billerica, Mass., headquarters.
Oscient Pharmaceuticals of Waltham, Mass., formerly Genome Therapeutics, has appointed three new vice presidents. Elenie Chadbourne has become vice president for drug safety and pharmacovigilance, joining the company from Genzyme. Kathleen Grim is the company’s new vice president for regulatory affairs. She comes to Oscient from Millennium Pharmaceuticals. Tracey Wielinski has joined Oscient as vice president of corporate qual-ity and compliance. Most recently, she worked at Abbott Laboratories’ MediSense business group.